Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.

Inhibition of Cdk4/Cdk6 by p18(INK4c) (p18) is pivotal for generation of noncycling immunoglobulin (Ig)-secreting plasma cells (PCs). In the absence of p18, CD138(+) plasmacytoid cells continue to cycle and turnover rapidly, suggesting that p18 controls PC homeostasis. We now show that p18 selectively acts in a rare population of rapidly cycling CD138(hi)/B220(hi) intermediate PCs (iPCs). While retaining certain B-cell signatures, iPCs are poised to differentiate to end-stage PCs although the majority undergo apoptosis. p18 is dispensable for the development of the PC transcriptional circuitry, and Blimp-1 and Bcl-6 are expressed fully and mutually exclusively in individual iPCs. However, a minor proportion of iPCs express both, and they are preferentially protected by p18 or Bcl-xL overexpression, consistent with expansion of the iPC pool by Bcl-xL overexpression, or loss of proapoptotic Bim or Noxa. Expression of Noxa is induced during B-cell activation, peaks in iPCs, and selectively repressed by p18. It is required to promote apoptosis of cycling B cells, especially in the absence of p18. These findings define the first physiologic function for Noxa and suggest that by repressing Noxa, induction of G₁ arrest by p18 bypasses a homeostatic cell-cycle checkpoint in iPCs for PC differentiation.

[1]  Andreas Radbruch,et al.  Chemotactic Responsiveness Toward Ligands for CXCR3 and CXCR4 Is Regulated on Plasma Blasts During the Time Course of a Memory Immune Response1 , 2002, The Journal of Immunology.

[2]  V. Godfrey,et al.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. , 1998, Genes & development.

[3]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[4]  D. Franklin,et al.  Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. , 1997, Immunity.

[5]  R. Noelle,et al.  Short-lived and Long-lived Bone Marrow Plasma Cells Are Derived from a Novel Precursor Population , 2002, The Journal of experimental medicine.

[6]  John Calvin Reed,et al.  Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. , 1997, Immunity.

[7]  K. Toellner,et al.  Heterogeneity of lymphoid tissue inducer cell populations present in embryonic and adult mouse lymphoid tissues , 2008, Immunology.

[8]  F. Finkelman,et al.  bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice , 1996, The Journal of experimental medicine.

[9]  Jun Zhang,et al.  Sites of specific B cell activation in primary and secondary responses to T cell‐dependent and T cell‐independent antigens , 1991, European journal of immunology.

[10]  Andreas Radbruch,et al.  Lifetime of plasma cells in the bone marrow , 1997, Nature.

[11]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[12]  M. Roussel,et al.  Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6 , 1995, Molecular and cellular biology.

[13]  J. Buerstedde,et al.  Loss of Pax5 promotes plasma cell differentiation. , 2006, Immunity.

[14]  S. Ely,et al.  CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. , 2002, Immunity.

[15]  R. Bataille,et al.  Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. , 2007, Cancer research.

[16]  Qiong Shen,et al.  Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination , 2006, Nature Immunology.

[17]  G. Morgan,et al.  Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.

[18]  P. Pandolfi,et al.  The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.

[19]  L. Staudt,et al.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.

[20]  M. Tourigny,et al.  Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response , 2000, The Journal of experimental medicine.

[21]  A. Strasser,et al.  Loss of the Pro-Apoptotic BH3-only Bcl-2 Family Member Bim Inhibits BCR Stimulation–induced Apoptosis and Deletion of Autoreactive B Cells , 2003, The Journal of experimental medicine.

[22]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[23]  G. Kelsoe,et al.  In situ studies of the primary immune response to (4-hydroxy-3- nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations , 1991, The Journal of experimental medicine.

[24]  T. Mak,et al.  Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.

[25]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[26]  D. R. Taylor,et al.  Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation , 1996, The Journal of experimental medicine.

[27]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[28]  J. Nevins,et al.  Regulation of the cyclin E gene by transcription factor E2F1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Hendrix,et al.  Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. , 2005, Cancer research.

[30]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[31]  Neal N. Iwakoshi,et al.  Plasma cell differentiation requires the transcription factor XBP-1 , 2001, Nature.

[32]  David L. Jaye,et al.  MTA3 and the Mi-2/NuRD Complex Regulate Cell Fate during B Lymphocyte Differentiation , 2004, Cell.

[33]  K. Calame,et al.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.

[34]  Kuo-I Lin,et al.  Blimp-1-Dependent Repression of Pax-5 Is Required for Differentiation of B Cells to Immunoglobulin M-Secreting Plasma Cells , 2002, Molecular and Cellular Biology.

[35]  D. Tenen,et al.  Defective B cell receptor‐mediated responses in mice lacking the Ets protein, Spi‐B , 1997, The EMBO journal.

[36]  S. Ely,et al.  Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[38]  Kenneth G. C. Smith,et al.  The phenotype and fate of the antibody‐forming cells of the splenic foci , 1996, European journal of immunology.

[39]  L. Staudt,et al.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.

[40]  Erinna F. Lee,et al.  Structural insights into the degradation of Mcl-1 induced by BH3 domains , 2007, Proceedings of the National Academy of Sciences.

[41]  R. Hardy,et al.  Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. , 1996, Immunity.

[42]  J. Cyster,et al.  Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.

[43]  K. Basso,et al.  BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells , 2005, Nature Immunology.

[44]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[45]  Roger Sciammas,et al.  Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. , 2006, Immunity.

[46]  D. Green,et al.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.